Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia—a nuclear magnetic resonance study

• Published in: International journal of cardiology Vol. 101; no. 3; pp. 441 - 447
• Main Authors: Ikewaki, Katsunori, Noma, Kenji, Tohyama, Jun-ichiro, Kido, Toshimi, Mochizuki, Seibu
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 08.06.2005; Elsevier Science
• Subjects: Bezafibrate; Bezafibrate - therapeutic use; Biological and medical sciences; Body Mass Index; C-Reactive Protein - metabolism; Cardiology. Vascular system; Chemokine CCL2 - blood; Cholesterol, HDL - blood; Cholesterol, VLDL - blood; Disorders of blood lipids. Hyperlipoproteinemia; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - diagnosis; Hypertriglyceridemia - drug therapy; Hypolipidemic Agents - therapeutic use; Inflammation - blood; Inflammatory marker; Interleukin-6 - blood; Lipoprotein; Lipoproteins - blood; Lipoproteins, HDL - blood; Lipoproteins, HDL3; Lipoproteins, LDL - blood; Magnetic Resonance Spectroscopy; Male; Medical sciences; Metabolic diseases; Middle Aged; Nephelometry and Turbidimetry; Nuclear magnetic resonance; Risk Factors; Triglyceride; Triglycerides - blood; Inflammatory marker; Lipoprotein; Nuclear magnetic resonance; Bezafibrate; Triglyceride; Human; Biological marker; Metabolic diseases; Lipids; Hyperlipoproteinemia; Inflammation; Enzymopathy; Phlebology; Hypertriglyceridemia; Circulatory system; Dyslipemia; Cardiology
• ISSN: 0167-5273; 1874-1754
• DOI: 10.1016/j.ijcard.2004.03.071

Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia. Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) were also determined. Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, p=0.0001). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm ( p=0.026). None of inflammation makers showed significant change by bezafibrate. Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects.